Your Catalyst To a Lucrative Business Human Milk Oligosaccharides (HMO) Market Size, Share, Growth, Trends, Outlook and Forecast to 2024 | Hexa Research “The global Human Milk Oligosaccharides (HMO) market size was valued at USD 60.0 million in 2015 and is expected to grow further over the forecast period.” 11 October 2018 – The global Human Milk Oligosaccharides (HMO) Market size is expected to reach USD 170.4 million by 2024. It is anticipated to expand at a CAGR of 12.3% over the forecast period.HMO is a bioactive complex sugar molecule, which promotes growth of healthy bacteria, such as bifid bacteria genus in human gut. It also and helps improve metabolic activity in human body. In addition, incorporation of HMO in the formulation of functional foods and beverages not only promotes growth of healthy bacteria but also eliminates harmful microbes such as salmonella, listeria, and campylobacter. High infant mortality rate coupled with rising demand for human milk donors in North America is one of the major drivers for the HMO market. North America accounted for around 25.0% of global market share in 2015 and is projected to expand further during the forecast period. Growing demand for infant food especially for infants with non-lactating mothers coupled with strong presence of infant formula manufacturers in U.S. is expected to have a positive impact on regional market. Besides North America, Europe is one of the key markets for human milk oligosaccharides. Presence of a large biotechnical institutes engaged in the development of enzyme formulations in Germany, U.K., and France is encouraging HMO manufacturers to establish tie-ups to improve their R&D activities. Browse Details of Report @ https://www.hexaresearch.com/research-report/human-milk-oligosaccharideshmo-market Follow Us: Your Catalyst To a Lucrative Business Over the past few years, many R&D institutes have launched chemically synthesizing techniques and cow milk processing methods for the production of HMO. Extraction of human milk oligosaccharides is a bit expensive due to the limited access to raw materials. Product innovations aimed at improving brain health, are expected to pose a threat to the existing market participants. According to the World Health Organization (WHO), the world population is expected rise by over a billion in the next 10 years. This factor is anticipated to propel demand for infant food, thereby driving the global market. The HMO is also useful for adults as it helps maintain health of the digestive system. The ingredient acts as a microbiota modulator and maintains health of the immune system. HMO also helps prevent T1D, which interacts between the innate immune system and intestinal microbes in adults. High demand for digestive health supplements among adults due to rising concerns regarding gastrointestinal disorders is expected to promote market growth. Some of the key manufacturers in the Human Milk Oligosaccharides (HMO) market include Inbiose; Jennewein Biotechnologie GmbH; Elicityl SA; Glycom A/S; ZuChem, Inc.; Medolac Laboratories; and Glycosyn LLC. Increased number of health claims in U.S. and several developed markets of Europe has spurred studies to explore the potential of HMO. These studies have derived different microbial challenges in gut, prevention of diarrhea, and protection from infectious diseases. In September 2013, ZuChem launched new HMO formulations including lgalactose, as well as sugar phosphates such as β-l-glucose-1-phosphate, α-d-galactose-1-phosphate, and β-l-xylose1-phosphate. In October 2014, U.S. based Madolac Laboratories completed construction of second phase of HMO purification plant. This plant will synthesize human milk oligosaccharides on a large scale, which will be further used in clinical trials and scientific research. Hexa Research has segmented the global human milk oligosaccharides (HMO) market report based on application and region:Segmentation by Application • Infant Formula • Functional Food & Beverages • Food Supplements • Others Segmentation by Region • North America • U.S. • Europe • U.K. • Germany • Asia Pacific • China Follow Us: Your Catalyst To a Lucrative Business • Japan • Latin America • Brazil • MEA Key players analyzed: • Inbiose NV • Elicityl S.A. • Jennewein Biotechnologie GmbH • Glycom A/S • Medolac Laboratories • ZuChem Inc. • Glycosyn LLC Browse Related Category Market Reports@ https://www.hexaresearch.com/researchcategory/nutraceuticals-and-functional-foods-industry Follow Us: Your Catalyst To a Lucrative Business Table of Content of Human Milk Oligosaccharides (HMO) Market Chapter 1 Research Methodology 1.1 Research Methodology 1.2 Research Scope & Assumptions 1.3 List of Data Sources Chapter 2 Executive Summary Chapter 3 HMO Industry Outlook 3.1 HMO Market Segmentation 3.2 HMO Market Size and Growth Prospects, 2013 - 2024 3.3 HMO - Value Chain Analysis 3.3.1 Vendor Landscape 3.4 Raw material Outlook 3.5 Technology Overview 3.6 Regulatory Framework 3.6.1 European Commission: Regulation (EC) No 258/97 of the European Parliament 3.7 HMO Market Dynamics 3.7.1 Market Driver Analysis 3.7.1.1 Positive Dairy Industry Outlook 3.7.1.2 Growing Dietary Supplements Market 3.7.1.3 Rising Concerns Towards Gut Health 3.7.2 Market Restraints Analysis 3.7.2.1 Lack of Technology for Large-scale Production 3.7.2.2 High R&D Cost 3.8 Key Opportunities Prioritized 3.9 HMO Competitive Landscape 3.10 HMO Porter’s Analysis 3.11 HMO Market PESTEL Analysis 3.12 Pricing Trends 2013 – 2024 Chapter 4 HMO Product Outlook 4.1 2’-Fucosyllactose (2’FL) 4.1.1 Specifications 4.1.2 Key Suppliers Follow Us: Your Catalyst To a Lucrative Business 4.1.3 Applications 4.1.4 Patents 4.1.5 Production Routes 4.1.6 Manufacturers 4.2 3’-Fucosyllactose (3’FL) 4.2.1 Specifications 4.2.2 Key Suppliers 4.2.3 Applications 4.2.4 Patents 4.2.5 Production Routes 4.2.6 Manufacturers 4.3 3’-Sialyllactose (3’SL) 4.3.1 Specifications 4.3.2 Key Suppliers 4.3.3 Application 4.3.4 Patents 4.3.5 Production Routes 4.3.6 Manufacturers 4.4 6’-Sialyllactose (6’SL) 4.4.1 Specifications 4.4.2 Key Suppliers 4.4.3 Applications 4.4.4 Patents 4.4.5 Production Routes 4.4.6 Manufacturers 4.5 Lacto-N-tetraose (LNT) 4.5.1 Specifications 4.5.2 Key Suppliers 4.5.3 Patents 4.5.4 Applications 4.5.5 Production Routes 4.5.6 Manufacturers 4.6 Lacto-N-neotetraose (LNnT) 4.6.1 Specifications 4.6.2 Key Suppliers 4.6.3 Patents Follow Us: Your Catalyst To a Lucrative Business 4.6.4 Applications 4.6.5 Production Routes 4.6.6 Manufacturers Chapter 5 HMO Application Outlook 5.1 Global HMO Market Volume Share by Application, 2015 & 2024 5.2 Infant Formula 5.2.1 Global HMO Market Estimates and Forecast in Infant Formula, 2013 - 2024 (Grams) (USD 000) 5.2.2 Global HMO Market Estimates and Forecast in Infant Formula, by Region, 2013 - 2024 (Grams) (USD 000) 5.3 Functional Food & Beverages 5.3.1 Global HMO Market Estimates and Forecast in Functional Food & Beverages, 2013 - 2024 (Grams) (USD 000) 5.3.2 Global HMO Market Estimates and Forecast in Functional Food & Beverages, by region, 2013 - 2024 (Grams) (USD 000) 5.4 Food Supplements 5.4.1 Global HMO Market Estimates and Forecast in Food Supplements, 2013 - 2024 (Grams) (USD 000) 5.4.2 Global HMO Market Estimates and Forecast in Food Supplements, by Region, 2013 - 2024 (Grams) (USD 000) 5.5 Others 5.5.1 Global HMO Market Estimates and Forecast in Other Applications, 2013 - 2024 (Grams) (USD 000) 5.5.2 Global HMO Market Estimates and Forecast in Other Applications, by Region, 20 13 - 2024 (Grams) (USD 000) Chapter 6 HMO Regional Outlook 6.1 Global HMO Market Volume Share by Region, 2015 & 2024 6.2 North America 6.2.1 North America HMO Market Estimates and Forecast, 2013 - 2024 (Grams) (USD 000) 6.2.2 North America HMO Market Estimates and Forecast, by Application, 2013 - 2024 (Grams) (USD 000) 6.2.3 U.S. 6.2.3.1 U.S. HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000) 6.2.3.2 U.S. HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD Follow Us: Your Catalyst To a Lucrative Business 000) 6.3 Europe 6.3.1 Europe HMO market estimates and forecast, 2012-2020 (Grams) (USD 000) 6.3.2 Europe HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD 000) 6.3.3 U.K. 6.3.3.1 U.K. HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000) 6.3.3.2 U.K. HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD 000) 6.3.4 Germany 6.3.4.1 Germany HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000) 6.3.4.2 Germany HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD 000) 6.4 Asia Pacific 6.4.1 Asia Pacific HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000) 6.4.2 Asia Pacific HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD 000) 6.4.3 China 6.4.3.1 China HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000) 6.4.3.2 China HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD 000) 6.4.4 Japan 6.4.4.1 Japan HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000) 6.4.4.2 Japan HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD 000) 6.5 Latin America 6.5.1 Latin America HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000) 6.5.2 Latin America HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD 000) 6.5.3 Brazil 6.5.3.1 Brazil HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000) 6.5.3.2 Brazil HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD 000) 6.6 MEA 6.6.1 MEA HMO market estimates and forecast, 2013 - 2024 (Grams) (USD 000) 6.6.2 MEA HMO market estimates and forecast, by application, 2013 - 2024 (Grams) (USD 000) Follow Us: Your Catalyst To a Lucrative Business Chapter 7 Competitive Landscape 7.1 Inbiose NV 7.1.1 Company Overview 7.1.2 Financial Performance 7.1.3 Product Benchmarking 7.1.4 Strategic Initiatives 7.2 Elicityl S.A. 7.2.1 Company Overview 7.2.2 Financial Performance 7.2.3 Product Benchmarking 7.2.4 Strategic Initiatives 7.3 Jennewein Biotechnologie GmbH 7.3.1 Company Overview 7.3.2 Financial Performance 7.3.3 Product Benchmarking 7.3.4 Strategic Initiatives 7.4 Glycom A/S 7.4.1 Company Overview 7.4.2 Financial Performance 7.4.3 Product Benchmarking 7.5 Medolac Laboratories 7.5.1 Company Overview 7.5.2 Financial Performance 7.5.3 Product Benchmarking 7.5.4 Strategic Initiatives 7.6 ZuChem Inc. 7.6.1 Company Overview 7.6.2 Financial Performance 7.6.3 Product Benchmarking 7.6.4 Strategic Initiatives 7.7 Glycosyn LLC 7.7.1 Company Overview 7.7.2 Financial Performance 7.7.3 Product Benchmarking Follow Us: Your Catalyst To a Lucrative Business About Us: Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Us: Ryan Shaw Hexa Research Felton Office Plaza 6265 Highway 9 Felton, California 95018 United States Phone: +1-800-489-3075 Email: [email protected] Website - https://www.hexaresearch.com Follow Us:
The global human milk oligosaccharides (HMO) market size is expected to reach USD 170.4 million by 2024.
© Copyright 2024 Paperzz
